ERBB2 and breast neoplasm: Among the 1070 breast tumors, 682 (64 %) were Luminal A (LA), 166 (16 %) were Luminal B HER2 negative (LBH−), 47 (4 %) were Luminal B HER2 positive (LBH+), 108 (10 %) were triple negative (TN) and 67 (6 %) were HER2-enriched tumors (H2+).